From ERα66 to ERα36: a generic method for validating a prognosis marker of breast tumor progression

BACKGROUND: Estrogen receptor alpha36 (ERalpha36), a variant of estrogen receptor alpha (ER) is expressed in about half of breast tumors, independently of the [ER+]/[ER-] status. In vitro, ERalpha36 triggers mitogenic non-genomic signaling and migration ability in response to 17beta-estradiol and ta...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:BMC Syst Biol
Asıl Yazarlar: Chamard-Jovenin, Clémence, Jung, Alain C., Chesnel, Amand, Abecassis, Joseph, Flament, Stéphane, Ledrappier, Sonia, Macabre, Christine, Boukhobza, Taha, Dumond, Hélène
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BioMed Central 2015
Konular:
Methodology Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4469423/
https://ncbi.nlm.nih.gov/pubmed/26080803
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12918-015-0178-7
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller